Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Enterprise Value (2016 - 2026)

Lexaria Bioscience's Enterprise Value history spans 12 years, with the latest figure at -$5.5 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$5.5 million for Q1 2026, up 20.31% from a year ago — trailing twelve months through Feb 2026 was -$5.5 million (up 20.31% YoY), and the annual figure for FY2025 was -$2.3 million, up 66.09%.
  • Enterprise Value for Q1 2026 was -$5.5 million at Lexaria Bioscience, down from -$4.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.8 million in Q3 2023 to a low of -$9.1 million in Q1 2022.
  • The 5-year median for Enterprise Value is -$5.2 million (2024), against an average of -$5.5 million.
  • The sharpest move saw Enterprise Value surged 71.56% in 2023, then tumbled 273.4% in 2024.
  • Year by year, Enterprise Value stood at -$5.1 million in 2022, then surged by 53.31% to -$2.4 million in 2023, then tumbled by 254.64% to -$8.5 million in 2024, then soared by 45.04% to -$4.7 million in 2025, then fell by 18.19% to -$5.5 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$5.5 million, -$4.7 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.